The Clinical Trials Office Core (CTO) provides comprehensive clinical trials resources and support to KCI members and affiliate institutions with the highest priority being the safety of participating subjects. The CTO functions to the highest ethical standards ensuring and maintaining compliance of KCI ciinicai trials with internal policies and external governing bodies. The primary and continuing goals ofthe CTO are to: ? Ensure that all clinical trials conducted at KCI are carried out in strict compliance with the Code of Federal Regulations (CFR) and in accordance with Intemationai Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. This is done in conjunction and with oversight by the Wayne State University Human Investigation Committee. ? Facilitate and optimize accrual to clinical trials by providing well qualified, specifically trained data management and research nurse support to KCI physicians and clinical support staff. ? Ensure research coordination by facilitating and optimizing physician-patient-CTO staff interaction, communication and collaboration. ? Facilitate regulatory approval and oversight to rapidly review and activate appropriate trials. The CTO coordinates and ensures compliance with the Data and Safety Monitoring Plan (DSMP), which irilSlu'des coordination and administrative support to the Protocol Review and Monitoring Committee, the Data and Safety Monitoring Committee and the Quality Assurance Committee. Additionally, the CTO serves as an interface with the protocol specific IRB of record to facilitate preparation of required regulatory documents necessary to expedite timely approval of KCI protocols. The CTO also coordinates registration and maintenance of all therapeutic protocols to the NCI's Clinical Trial Reporting Program and ClinicalTrials.gov. CTO supports NCI-funded peer reviewed protocols, investigator-initiated studies, industry sponsored protocols and the cooperative group protocols of SWOG, COG, GOG, RTOG, as well as other specialty cooperative groups. Over 80 FTEs provide data management services as members of the CTO in support of approximately 350 active protocols. These activities have resulted in a 76% increase in accrual to therapeutic clinical trials during this grant period with representation of minorities and women that reflect the communitv that KCI serves.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600878
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$543,259
Indirect Cost
$185,853
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017

Showing the most recent 10 out of 826 publications